Sector News

Hung, ex-Medivation execs join forces for stealthy cancer startup

October 28, 2019
Life sciences

David Hung, M.D., has had a strange few years: From the man who led Medivation to being snapped up by Pfizer in a major $14 billion M&A deal, he then went over to Axovant, where it went very wrong.

He’s now looking to turn things around. Last year, he quietly founded a new oncology company known as Nuvation Bio, and he’s clearly been busy meeting the money men and women because today, it’s seen a massive $275 million series A.

This mammoth round was “led, structured and syndicated” by Omega Funds, it said in a statement, with a host of others chipping in, including: Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (a global Asia-based investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel company) and other institutional investors.

As you’d expect at this stage, there’s little detail around its pipeline. The money will “enable Nuvation Bio to expand its development activities and advance a number of its oncology programs,” and though launching today, it’s still in stealth mode, so don’t expect much more for now.

Looking a little deeper, all that’s on offer is that it is “focused on the development of next generation therapies that will target the foremost unmet needs in oncology […] Nuvation Bio’s proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates.” But that’s all she wrote.

Hung, who will serve as CEO and president, will hope to have a better time of it than he did at Vivek Ramaswamy’s Axovant biotech, which saw big raises and an IPO based on the hopes of some old Alzheimer’s disease therapies that turned out to be duds.

Hung ran the Axovant show, but when it went south, he took a professional hit. Axovant later pivoted to gene therapies, and now Hung appears to be returning back to his biotech roots in cancer, the focus of his former company Medivation. As well as that experience, he’s also bringing much of his old Medivation team for the Nuvation ride.

“My vision for Nuvation Bio is to provide patients with dramatic medical advancements that address their unmet needs across a wide range of oncology applications,” he said.

“I am extremely proud of what we accomplished at Medivation, developing in just seven years what is now the world’s largest prostate cancer drug. However, I believe we could have done so much more had we had more time. With seven mechanistically distinct programs at Nuvation Bio, along with the strong support of Omega Funds and a formidable syndicate of investors, we are well-positioned to expand upon the mission we started at Medivation. My team and I are extremely excited to develop even more game-changing therapies for the foremost unmet needs in oncology.”

“The whole Omega Funds’ team has been thrilled to partner with David on the launch and Series A syndication of Nuvation Bio and thanks to deal leads Richard Lim and Michelle Doig for their efforts executing this transaction,” added Otello Stampacchia, Ph.D., founder and managing director of Omega Funds.

“The breadth and depth of Nuvation Bio’s innovative pipeline demands a large initial investment. By syndicating one of the largest-ever Series A biotech financings, David and his exceptional team are well-positioned to advance Nuvation Bio’s deep portfolio of therapies focused on dramatically improving the standard of care for those living with cancer.”

By Ben Adams

Source: Fierce Biotech

1 response to “Hung, ex-Medivation execs join forces for stealthy cancer startup

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 10, 2021

Merck to acquire German contract development company AmpTec

Life sciences

The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.

January 10, 2021

Goodbye pill, hello science: Pfizer debuts redesigned logo with double helix

Life sciences

It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.

January 10, 2021

Fujifilm triples down on viral vector manufacturing with new $40M Boston site

Life sciences

The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.

Send this to a friend